Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Dizal (Jiangsu) Pharmaceutical Company Limited
Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
May 27, 2026
Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
May 8, 2026
Dizal’s ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
May 5, 2026
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
May 4, 2026